September 20th 2024
Peptides are increasingly used in cosmeceuticals for their ability to enhance cellular communication and functionality in antiaging formulations.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Time will define Juvederm's place among HA fillers
January 1st 2007National report - Many in dermatology are anxiously anticipating the arrival of the latest addition to the hyaluronic acid filler market, Juvederm (Allergan Medical), as a new alternative to the long-held gold standard, Restylane (Medicis ?sthetics).
Combination treatment shows efficacy in facial hair removal
January 1st 2007National report - Laser photoepilation is considered the gold standard of treatment for the removal of unwanted facial hair in women. A recent study shows that combining eflornithine cream (Vaniqa, SkinMedica) with laser therapy can safely and effectively reduce the growth of hair as well as speed up the hair removal process, as compared to laser epilation therapy alone.
Combination treatment shows efficacy in facial hair removal
January 1st 2007National report - Laser photoepilation is considered the gold standard of treatment for the removal of unwanted facial hair in women. A recent study shows that combining eflornithine cream (Vaniqa, SkinMedica) with laser therapy can safely and effectively reduce the growth of hair as well as speed up the hair removal process, as compared to laser epilation therapy alone.
Time will define Juvederm's place among HA fillers
January 1st 2007National report - Many in dermatology are anxiously anticipating the arrival of the latest addition to the hyaluronic acid filler market, Juvederm (Allergan Medical), as a new alternative to the long-held gold standard, Restylane (Medicis ?sthetics).
Straight talk about cosmeceuticals
January 1st 2007New Orleans - The problem with today's cosmeceutical advertising is that it oversells the benefits of products in the marketplace, says Patricia K. Farris, M.D., a dermatologist who practices in New Orleans and is a clinical assistant professor in the department of dermatology at Tulane University.
New toxins: A perspective from two continents
January 1st 2007Palm Springs, Calif. - Botox (botulinum toxin type A, Allergan) offers patients with moderate-to-severe glabellar lines longer lasting efficacy and greater treatment satisfaction compared with those patients treated with Dysport (botulinum toxin type A, Ipsen Limited), according to one expert.